Conference
Outcomes of Patients with Brain Metastases from Renal Cell Carcinoma Receiving First-line Therapies: Results from the International Metastatic Renal Cell Carcinoma Database Consortium
Abstract
Patients with brain metastases (BrM) from renal cell carcinoma and their outcomes are not well characterized owing to frequent exclusion of this population from clinical trials. We analyzed data for patients with or without BrM using the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC). A total of 389/4799 patients (8.1%) had BrM on initiation of systemic therapy. First-line immuno-oncology (IO)-based combination therapy …
Authors
Takemura K; Lemelin A; Ernst MS; Wells JC; Saliby RM; El Zarif T; Labaki C; Basappa NS; Szabados B; Powles T
Volume
86
Pagination
pp. 488-492
Publisher
Elsevier
Publication Date
December 2024
DOI
10.1016/j.eururo.2024.01.006
Conference proceedings
European Urology
Issue
6
ISSN
0302-2838